Loading
Some cancer proteins sit on the cell surface or float outside cells, where protein-destroying drugs cannot reach. A different trick can drag them inside to be broken down.
Lysosome-targeting chimeras (LYTACs) and antibody-based equivalents (KineTACs) use receptors such as the cation-independent mannose-6-phosphate receptor or ASGPR to internalise and degrade extracellular and membrane proteins. Cancer targets that resist antibody blockade because they are shed, recycled or in excess (for example growth factors, immunosuppressive ligands, and non-internalising surface antigens) become tractable.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.